Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 24Terminated 8Recruiting 6Withdrawn 3Unknown 3Active not recruiting 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 98Lymphoid 49Other hematologic neoplasm 38Thoracic 7Genitourinary 6Gastrointestinal 5CNS 4Breast 4Tumor-Agnostic 3Myeloid 3Gynecologic 2Other solid neoplasm 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 76pembrolizumab 74enzalutamide 57Radiosurgery 57Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 43Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Biopsy 31Cisplatin 30Carboplatin 29apalutamide 28Standard of Care 28cabozantinib 27Pluvicto 27abiraterone 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 23X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Dexamethasone × Genitourinary × Clear all
NCT06136650 2026-06-03

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06616597 2026-02-19

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
58 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Astellas Pharma Inc

Phase 1 Recruiting
174 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡